news

finance

Technology

Sorrento Therapeutics soars 44% after FDA green-lights COVID-19 antibody trial

Even before Thursday’s gains, Sorrento’s stock had surged 147% year-to-date amid optimism around its COVID-19 treatment.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *